SITC's Cancer Immunotherapy Guidelines program is a collection of clinical practice guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure recommendations are unbiased, transparent, and balanced.
The lung cancer and mesothelioma guideline provides a valuable clinical decision-making tool to help guide oncologists and other advanced practice providers on topics including biomarkers, the selection of appropriate immunotherapeutic regimens, treatment response and monitoring, toxicity management, and patient quality of life considerations.
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma" originally published in Journal for Immunotherapy of Cancer (JITC) on May 31, 2022.
SITC continuously evaluates the field for practice-changing data and new FDA approvals. The SITC Lung Cancer and Mesothelioma Expert Panel will guide the development of updates within this CPG. Updates will appear in the SITC CPG Mobile App and as annotated text accompanying the original publication in JITC.
SITC is pleased to offer companion education resources in support of the lung cancer and mesothelioma CPG. These activities feature faculty comprised of the guideline Expert Panel and are designed to provide a deeper understanding of the recommendations in SITC guidelines and how to apply them in various clinical scenarios. Below is a list of the available guideline education resources for the lung cancer and mesothelioma CPG, including one-hour webinars that provide in-depth insights into guideline recommendations, as well as mini-modules focusing on specific topics within the content. Videos are available free and on-demand.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com